WHO To Assess Impact Of Biological Qualifier Scheme
This article was originally published in SRA
Executive Summary
The World Health Organization is looking for an outside body to assess the expected impact of its planned 'biological qualifier' for biological medicines (BQ) on stakeholders because of the many divergent opinions that have been expressed over the proposal, which was finalized last year and has now been published1,2.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.